Michael J. Mauro
About
Michael J. Mauro is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, Michael J. Mauro has authored 234 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 222 papers in Hematology, 170 papers in Genetics and 88 papers in Rheumatology. Recurrent topics in Michael J. Mauro's work include Chronic Myeloid Leukemia Treatments (216 papers), Chronic Lymphocytic Leukemia Research (153 papers) and Eosinophilic Disorders and Syndromes (86 papers). Michael J. Mauro is often cited by papers focused on Chronic Myeloid Leukemia Treatments (216 papers), Chronic Lymphocytic Leukemia Research (153 papers) and Eosinophilic Disorders and Syndromes (86 papers). Michael J. Mauro collaborates with scholars based in United States, Germany and France. Michael J. Mauro's co-authors include Brian Druker, Jörge E. Cortes, Michael W. Deininger, Michael O’Dwyer, Andreas Hochhaus, Hagop M. Kantarjian, Moshe Talpaz, Richard T. Maziarz, Richard D. Press and Charles Chuah and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Michael J. Mauro
224 papers receiving 5.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael J. Mauro United States | 40 | 3.9k | 3.1k | 2.1k | 918 | 825 | 234 | 5.3k | ||
| Susan O’Brien United States | 34 | 4.4k 1.1× | 3.5k 1.1× | 1.9k 0.9× | 1.0k 1.1× | 867 1.1× | 73 | 5.9k | ||
| Stephen G. O’Brien United Kingdom | 23 | 3.8k 1.0× | 3.1k 1.0× | 2.1k 1.0× | 663 0.7× | 487 0.6× | 43 | 4.5k | ||
| Hans D. Menssen Switzerland | 26 | 2.0k 0.5× | 1.5k 0.5× | 882 0.4× | 1.0k 1.1× | 772 0.9× | 64 | 3.5k | ||
| H. Kantarjian United States | 29 | 2.4k 0.6× | 2.1k 0.7× | 776 0.4× | 637 0.7× | 995 1.2× | 120 | 3.9k | ||
| Tamás Masszi Hungary | 30 | 3.8k 1.0× | 2.3k 0.8× | 948 0.5× | 2.3k 2.5× | 2.3k 2.7× | 188 | 6.1k | ||
| Elisabetta Abruzzese Italy | 27 | 2.5k 0.6× | 1.8k 0.6× | 1.1k 0.5× | 538 0.6× | 399 0.5× | 150 | 3.2k | ||
| Nikolas von Bubnoff Germany | 31 | 2.0k 0.5× | 1.3k 0.4× | 683 0.3× | 1.1k 1.2× | 1.1k 1.4× | 138 | 4.1k | ||
| Shu Tamura Japan | 8 | 2.5k 0.6× | 1.6k 0.5× | 1.1k 0.5× | 713 0.8× | 1.0k 1.2× | 11 | 3.7k | ||
| Susan Branford Australia | 43 | 9.7k 2.4× | 8.1k 2.7× | 5.3k 2.5× | 1.3k 1.4× | 1.1k 1.4× | 200 | 11.0k | ||
| Gerald M. Segal United States | 13 | 2.5k 0.6× | 1.4k 0.5× | 846 0.4× | 628 0.7× | 953 1.2× | 20 | 3.9k |
Countries citing papers authored by Michael J. Mauro
Since
Specialization
Citations
This map shows the geographic impact of Michael J. Mauro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Mauro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Mauro more than expected).
Fields of papers citing papers by Michael J. Mauro
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael J. Mauro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Mauro. The network helps show where Michael J. Mauro may publish in the future.
Co-authorship network of co-authors of Michael J. Mauro
This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Mauro. A scholar is included among the top collaborators of Michael J. Mauro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Mauro. Michael J. Mauro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mauro, Michael J., Rüdiger Hehlmann, Loretta A. Williams, et al.. (2025). Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY. Leukemia & lymphoma. 66(9). 1615–1624.
2.
Jabbour, Elias, Timothy P. Hughes, Richard Van Etten, et al.. (2025). CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML. Blood. 146(Supplement 1). 901–901.
3.
Cortes, Jörge E., Fabian Lang, Delphine Réa, et al.. (2025). Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia. 39(5). 1124–1134.
4.
Atallah, Ehab, Michael J. Mauro, Koji Sasaki, et al.. (2024). Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncology. 20(38). 3065–3075.
5.
Deininger, Michael W., Jane Apperley, Christopher Arthur, et al.. (2024). Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.. Journal of Clinical Oncology. 42(16_suppl). 6501–6501.
6.
Atallah, Ehab, Michael S. Broder, Onyee Chan, et al.. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. 144(Supplement 1). 5052–5052.
7.
Moslehi, Javid J., Mandar A. Aras, Vivian G. Oehler, et al.. (2023). Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.. Journal of Clinical Oncology. 41(16_suppl). 7053–7053.
8.
Bewersdorf, Jan Philipp, Andriy Derkach, Lucia Masárová, et al.. (2023). A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood. 142(Supplement 1). 6440–6440.
9.
Brümmendorf, Tim H., Jörge E. Cortes, Dragana Milojković, et al.. (2022). Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 36(7). 1825–1833.
10.
Sweet, Kendra, Jörge E. Cortes, Jane F. Apperley, et al.. (2022). Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clinical Cancer Research. 29(12). 2179–2183.
11.
Réa, Delphine, Michael J. Mauro, Jörge E. Cortes, et al.. (2020). COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Blood. 136(Supplement 1). 46–47.
12.
Wang, Qian, Changchuan Jiang, Yaning Zhang, et al.. (2020). Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis. Leukemia & lymphoma. 61(5). 1147–1157.
13.
Branford, Susan, Dennis Dong Hwan Kim, Jane F. Apperley, et al.. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 33(8). 1835–1850.
14.
Rampal, Raajit K., Srđan Verstovšek, Sean M. Devlin, et al.. (2019). Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood. 134(Supplement_1). 4163–4163.
15.
Spiciarich, David R., Stephen T. Oh, Michael J. Mauro, et al.. (2018). A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer Research. 78(24). 6762–6770.
16.
Hehlmann, Rüdiger, Jörge E. Cortes, Teresa Zyczynski, et al.. (2018). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology. 94(1). 46–54.
17.
Zaleta, Alexandra K., M. F. Miller, Shauna McManus, et al.. (2017). Symptom Burden, Palliative Care Needs, and Patient-Provider Communication Among Chronic Myeloid Leukemia Survivors. Blood. 130. 4704.
18.
Goldberg, Aaron D., Troy Z. Horvat, Meier Hsu, et al.. (2017). Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies. Blood. 130. 1353–1353.
19.
Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, et al.. (2017). Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. Blood. 130. 2875–2875.
20.
Mauro, Michael J.. (2009). Response Dynamics in Chronic-Phase Chronic Myeloid Leukemia. Clinical Lymphoma & Myeloma. 9(3). 217–222.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Stephen G. O’Brien Breakdown of academic impact, for papers by Hans D. Menssen Breakdown of academic impact, for papers by H. Kantarjian Breakdown of academic impact, for papers by Tamás Masszi Breakdown of academic impact, for papers by Elisabetta Abruzzese Breakdown of academic impact, for papers by Nikolas von Bubnoff Breakdown of academic impact, for papers by Shu Tamura Breakdown of academic impact, for papers by Susan Branford Breakdown of academic impact, for papers by Gerald M. Segal